Sertraline versus imipramine to prevent relapse in chronic depression

Lorrin M. Koran, Alan J. Gelenberg, Susan G. Kornstein, Robert H. Howland, Richard A. Friedman, Charles DeBattista, Daniel Klein, James H. Kocsis, Alan F. Schatzberg, Michael E. Thase, A. John Rush, Robert M A Hirschfeld, Lisa M. LaVange, Martin B. Keller

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: Chronic depressions are common, disabling and under-treated, and long-term treatment is little studied. We report the continuation phase results from a long-term treatment study. Methods: After 12 weeks of acute phase treatment in a double-blind, randomized, parallel-group, multi-center trial of sertraline or imipramine, patients with chronic depression (≥2 years in major depression, or major depression superimposed on dysthymia) continued study drug for 16 weeks. Initially, 635 patients were randomized to sertraline or imipramine in a 2:1 ratio. Nonresponders after 12 weeks entered a 12-week double-blind crossover trial of the alternate medication. Entry into continuation treatment required at least a satisfactory response (partial remission) to initial or crossover treatment. Results: Of 239 acute or crossover responders to sertraline, 60% entered continuation in full remission and 40% with a partial remission. These proportions were identical for imipramine patients (n=147). For both drug groups, over two-thirds of those entering in full remission retained it. For those entering in partial remission, over 40% achieved full remission. Patients requiring crossover treatment were less likely to maintain or improve their response during continuation treatment. The two drugs did not differ significantly in response distribution, drop out rates or discontinuation due to side effects during continuation treatment. Limitations: The absence of a placebo group constrains interpretation of our results, but chronic depressions have low placebo response rates. Conclusions: Most chronic depression patients who remit with 12 weeks of sertraline or imipramine treatment maintain remission during 16 weeks of continuation treatment. Most patients with a satisfactory therapeutic response (partial remission) after 12 weeks of treatment maintain it or further improve. Patients treated with imipramine experienced more side effects, but both drugs were well tolerated.

Original languageEnglish (US)
Pages (from-to)27-36
Number of pages10
JournalJournal of Affective Disorders
Volume65
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Sertraline
Imipramine
Recurrence
Therapeutics
Placebos
Pharmaceutical Preparations
Drug-Related Side Effects and Adverse Reactions
Cross-Over Studies

Keywords

  • Chronic depression
  • Continuation phase treatment
  • Dysthymia
  • Imipramine
  • Sertraline

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Koran, L. M., Gelenberg, A. J., Kornstein, S. G., Howland, R. H., Friedman, R. A., DeBattista, C., ... Keller, M. B. (2001). Sertraline versus imipramine to prevent relapse in chronic depression. Journal of Affective Disorders, 65(1), 27-36. https://doi.org/10.1016/S0165-0327(00)00272-X

Sertraline versus imipramine to prevent relapse in chronic depression. / Koran, Lorrin M.; Gelenberg, Alan J.; Kornstein, Susan G.; Howland, Robert H.; Friedman, Richard A.; DeBattista, Charles; Klein, Daniel; Kocsis, James H.; Schatzberg, Alan F.; Thase, Michael E.; Rush, A. John; Hirschfeld, Robert M A; LaVange, Lisa M.; Keller, Martin B.

In: Journal of Affective Disorders, Vol. 65, No. 1, 2001, p. 27-36.

Research output: Contribution to journalArticle

Koran, LM, Gelenberg, AJ, Kornstein, SG, Howland, RH, Friedman, RA, DeBattista, C, Klein, D, Kocsis, JH, Schatzberg, AF, Thase, ME, Rush, AJ, Hirschfeld, RMA, LaVange, LM & Keller, MB 2001, 'Sertraline versus imipramine to prevent relapse in chronic depression', Journal of Affective Disorders, vol. 65, no. 1, pp. 27-36. https://doi.org/10.1016/S0165-0327(00)00272-X
Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C et al. Sertraline versus imipramine to prevent relapse in chronic depression. Journal of Affective Disorders. 2001;65(1):27-36. https://doi.org/10.1016/S0165-0327(00)00272-X
Koran, Lorrin M. ; Gelenberg, Alan J. ; Kornstein, Susan G. ; Howland, Robert H. ; Friedman, Richard A. ; DeBattista, Charles ; Klein, Daniel ; Kocsis, James H. ; Schatzberg, Alan F. ; Thase, Michael E. ; Rush, A. John ; Hirschfeld, Robert M A ; LaVange, Lisa M. ; Keller, Martin B. / Sertraline versus imipramine to prevent relapse in chronic depression. In: Journal of Affective Disorders. 2001 ; Vol. 65, No. 1. pp. 27-36.
@article{67c2fdd67567494a803bb86005f86525,
title = "Sertraline versus imipramine to prevent relapse in chronic depression",
abstract = "Background: Chronic depressions are common, disabling and under-treated, and long-term treatment is little studied. We report the continuation phase results from a long-term treatment study. Methods: After 12 weeks of acute phase treatment in a double-blind, randomized, parallel-group, multi-center trial of sertraline or imipramine, patients with chronic depression (≥2 years in major depression, or major depression superimposed on dysthymia) continued study drug for 16 weeks. Initially, 635 patients were randomized to sertraline or imipramine in a 2:1 ratio. Nonresponders after 12 weeks entered a 12-week double-blind crossover trial of the alternate medication. Entry into continuation treatment required at least a satisfactory response (partial remission) to initial or crossover treatment. Results: Of 239 acute or crossover responders to sertraline, 60{\%} entered continuation in full remission and 40{\%} with a partial remission. These proportions were identical for imipramine patients (n=147). For both drug groups, over two-thirds of those entering in full remission retained it. For those entering in partial remission, over 40{\%} achieved full remission. Patients requiring crossover treatment were less likely to maintain or improve their response during continuation treatment. The two drugs did not differ significantly in response distribution, drop out rates or discontinuation due to side effects during continuation treatment. Limitations: The absence of a placebo group constrains interpretation of our results, but chronic depressions have low placebo response rates. Conclusions: Most chronic depression patients who remit with 12 weeks of sertraline or imipramine treatment maintain remission during 16 weeks of continuation treatment. Most patients with a satisfactory therapeutic response (partial remission) after 12 weeks of treatment maintain it or further improve. Patients treated with imipramine experienced more side effects, but both drugs were well tolerated.",
keywords = "Chronic depression, Continuation phase treatment, Dysthymia, Imipramine, Sertraline",
author = "Koran, {Lorrin M.} and Gelenberg, {Alan J.} and Kornstein, {Susan G.} and Howland, {Robert H.} and Friedman, {Richard A.} and Charles DeBattista and Daniel Klein and Kocsis, {James H.} and Schatzberg, {Alan F.} and Thase, {Michael E.} and Rush, {A. John} and Hirschfeld, {Robert M A} and LaVange, {Lisa M.} and Keller, {Martin B.}",
year = "2001",
doi = "10.1016/S0165-0327(00)00272-X",
language = "English (US)",
volume = "65",
pages = "27--36",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Sertraline versus imipramine to prevent relapse in chronic depression

AU - Koran, Lorrin M.

AU - Gelenberg, Alan J.

AU - Kornstein, Susan G.

AU - Howland, Robert H.

AU - Friedman, Richard A.

AU - DeBattista, Charles

AU - Klein, Daniel

AU - Kocsis, James H.

AU - Schatzberg, Alan F.

AU - Thase, Michael E.

AU - Rush, A. John

AU - Hirschfeld, Robert M A

AU - LaVange, Lisa M.

AU - Keller, Martin B.

PY - 2001

Y1 - 2001

N2 - Background: Chronic depressions are common, disabling and under-treated, and long-term treatment is little studied. We report the continuation phase results from a long-term treatment study. Methods: After 12 weeks of acute phase treatment in a double-blind, randomized, parallel-group, multi-center trial of sertraline or imipramine, patients with chronic depression (≥2 years in major depression, or major depression superimposed on dysthymia) continued study drug for 16 weeks. Initially, 635 patients were randomized to sertraline or imipramine in a 2:1 ratio. Nonresponders after 12 weeks entered a 12-week double-blind crossover trial of the alternate medication. Entry into continuation treatment required at least a satisfactory response (partial remission) to initial or crossover treatment. Results: Of 239 acute or crossover responders to sertraline, 60% entered continuation in full remission and 40% with a partial remission. These proportions were identical for imipramine patients (n=147). For both drug groups, over two-thirds of those entering in full remission retained it. For those entering in partial remission, over 40% achieved full remission. Patients requiring crossover treatment were less likely to maintain or improve their response during continuation treatment. The two drugs did not differ significantly in response distribution, drop out rates or discontinuation due to side effects during continuation treatment. Limitations: The absence of a placebo group constrains interpretation of our results, but chronic depressions have low placebo response rates. Conclusions: Most chronic depression patients who remit with 12 weeks of sertraline or imipramine treatment maintain remission during 16 weeks of continuation treatment. Most patients with a satisfactory therapeutic response (partial remission) after 12 weeks of treatment maintain it or further improve. Patients treated with imipramine experienced more side effects, but both drugs were well tolerated.

AB - Background: Chronic depressions are common, disabling and under-treated, and long-term treatment is little studied. We report the continuation phase results from a long-term treatment study. Methods: After 12 weeks of acute phase treatment in a double-blind, randomized, parallel-group, multi-center trial of sertraline or imipramine, patients with chronic depression (≥2 years in major depression, or major depression superimposed on dysthymia) continued study drug for 16 weeks. Initially, 635 patients were randomized to sertraline or imipramine in a 2:1 ratio. Nonresponders after 12 weeks entered a 12-week double-blind crossover trial of the alternate medication. Entry into continuation treatment required at least a satisfactory response (partial remission) to initial or crossover treatment. Results: Of 239 acute or crossover responders to sertraline, 60% entered continuation in full remission and 40% with a partial remission. These proportions were identical for imipramine patients (n=147). For both drug groups, over two-thirds of those entering in full remission retained it. For those entering in partial remission, over 40% achieved full remission. Patients requiring crossover treatment were less likely to maintain or improve their response during continuation treatment. The two drugs did not differ significantly in response distribution, drop out rates or discontinuation due to side effects during continuation treatment. Limitations: The absence of a placebo group constrains interpretation of our results, but chronic depressions have low placebo response rates. Conclusions: Most chronic depression patients who remit with 12 weeks of sertraline or imipramine treatment maintain remission during 16 weeks of continuation treatment. Most patients with a satisfactory therapeutic response (partial remission) after 12 weeks of treatment maintain it or further improve. Patients treated with imipramine experienced more side effects, but both drugs were well tolerated.

KW - Chronic depression

KW - Continuation phase treatment

KW - Dysthymia

KW - Imipramine

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=0035017344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035017344&partnerID=8YFLogxK

U2 - 10.1016/S0165-0327(00)00272-X

DO - 10.1016/S0165-0327(00)00272-X

M3 - Article

C2 - 11426506

AN - SCOPUS:0035017344

VL - 65

SP - 27

EP - 36

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1

ER -